REQUEST A DEMO
Total
USD $0.00
Search more companies

Roche d.o.o. (Bosnia and Herzegovina)

Main Activities: Drugs and Druggists' Sundries Merchant Wholesalers
Full name: Roche d.o.o. Profile Updated: October 09, 2023
Buy our report for this company USD 29.95 Most recent financial data: 2021 Available in: English Download a sample report

Roche Bosna i Hercegovina is a biotech company specializing in the development of prescription drugs, particularly in the field of biotechnology, with a focus on personalized medicine, early detection, prevention, diagnosis, and treatment of diseases, including oncology, immune, infectious diseases, ophthalmology, and diseases of the central nervous system. Roche is also involved in the development of reliable tests for COVID-19 and continues to innovate new drugs targeting a wide range of diseases.

Headquarters
Zmaja Od Bosne Br. 7 Str.
Sarajevo - Novo Sarajevo; Sarajevo; Postal Code: 71120

Contact Details: Purchase the Roche d.o.o. report to view the information.

Website: http://www.roche.ba

Basic Information
Total Employees:
Purchase the Roche d.o.o. report to view the information.
Outstanding Shares:
Purchase the Roche d.o.o. report to view the information.
Registered Capital:
Purchase the Roche d.o.o. report to view the information.
Incorporation Date:
Key Executives
Purchase this report to view the information.
Director
Ownership Details
Purchase this report to view the information.
97%
Company Performance
Financial values in the chart are available after Roche d.o.o. report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency BAM. Absolute financial data is included in the purchased report.
Net sales revenue
12.54%
Total operating revenue
12.54%
Operating profit (EBIT)
368.83%
EBITDA
93.32%
Net Profit (Loss) for the Period
-9.48%
Total assets
14.75%
Total equity
3.1%
Operating Profit Margin (ROS)
1.7%
Net Profit Margin
-0.27%
Return on Equity (ROE)
-0.29%
Debt to Equity Ratio
-0.59%
Quick Ratio
-0.04%
Cash Ratio
-0.13%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?